Ovarian Reserve
Introduction
Section titled “Introduction”Ovarian reserve refers to the reproductive potential of a woman’s ovaries, specifically the number and quality of oocytes (egg cells) remaining. This reserve is finite, established before birth, and naturally declines throughout a woman’s life, eventually leading to menopause. The rate of this decline varies significantly among individuals, influencing their reproductive lifespan and fertility window.
Biological Basis
Section titled “Biological Basis”The biological basis of ovarian reserve lies in the pool of primordial follicles within the ovaries, each containing an immature oocyte. Over time, these follicles are recruited and mature, or undergo atresia (degeneration). Key hormonal markers are used to assess ovarian reserve, including Anti-Müllerian Hormone (AMH), which is produced by small antral follicles and reflects the size of the remaining follicular pool, and Follicle-Stimulating Hormone (FSH), which typically rises as ovarian reserve declines. An Antral Follicle Count (AFC), performed via ultrasound, also provides a direct visual estimate of the number of small follicles available. Genetic factors are known to play a role in determining both the initial ovarian reserve and the rate at which it declines, influencing a woman’s reproductive timeline and susceptibility to various gynecologic conditions.[1]
Clinical Relevance
Section titled “Clinical Relevance”Clinically, assessing ovarian reserve is crucial for individuals planning conception, particularly those considering assisted reproductive technologies (ART) such as in vitro fertilization (IVF). It helps fertility specialists predict a woman’s response to ovarian stimulation and provides an indication of her chances of successful pregnancy. Low ovarian reserve can be a factor in infertility and may indicate conditions like premature ovarian insufficiency (POI) or early menopause, requiring personalized fertility management strategies.
Social Importance
Section titled “Social Importance”The concept of ovarian reserve holds significant social importance in contemporary society. With increasing trends in delayed childbearing, understanding and assessing ovarian reserve allows individuals and couples to make informed decisions about family planning. It informs discussions around fertility preservation options, such as egg freezing, for those who wish to postpone pregnancy for personal or medical reasons. The variability in ovarian aging highlights the diverse reproductive experiences among women and underscores the need for personalized reproductive health guidance.
Limitations
Section titled “Limitations”Understanding the genetic underpinnings of complex reproductive traits like ovarian reserve is subject to several methodological, statistical, and generalizability limitations. These constraints impact the precision of causal inference, the breadth of applicability of findings, and the comprehensiveness of our current knowledge. Acknowledging these limitations is crucial for accurate interpretation of research and for guiding future investigations.
Methodological and Statistical Constraints
Section titled “Methodological and Statistical Constraints”Genetic studies often face challenges related to study design and statistical rigor that can affect the robustness of findings for ovarian reserve. Power limitations are frequently encountered, particularly in analyses focused on specific ancestry groups, where sample sizes may be insufficient to detect subtle genetic associations or perform detailed analyses like pathway enrichment.[2] Similarly, tissue-specific genetic expression studies can be underpowered due to a limited number of samples available for certain tissue models, such as the uterine tissue model, which can hinder the detection of significant associations.[2]Methodological biases, such as the “winner’s curse,” can inflate effect size estimates in initial discovery stages, necessitating careful validation in independent cohorts to ensure accurate reporting of effect magnitudes.[3] Moreover, heritability analyses, like those employing methods such as SumHer, can sometimes overestimate heritability, although reported estimates often remain consistent with other approaches.[2] Mendelian Randomization (MR) analyses, while powerful for inferring causality, are also subject to specific limitations. A primary concern is horizontal pleiotropy, where genetic instruments affect the outcome through pathways independent of the exposure, potentially biasing causal estimates.[4], [5], [6] Various sensitivity analyses, including MR-Egger and MR-PRESSO, are employed to test for and mitigate such pleiotropy, but some of these analyses may be considered exploratory, lacking multiple testing correction.[4] Additionally, weak instrument bias or the presence of extreme outliers can compromise MR findings, necessitating robust sensitivity analyses like MR-RAPS.[5] Furthermore, meta-analyses combining data from multiple studies may encounter significant heterogeneity, requiring the use of random-effects models to account for variability across cohorts.[7] The potential for considerable sample overlap among GWAS datasets used in meta-analyses can also introduce bias and affect the independence of findings.[8]
Generalizability and Phenotypic Representation
Section titled “Generalizability and Phenotypic Representation”A significant limitation in genetic research on ovarian reserve, as with many complex traits, is the generalizability of findings across diverse populations. Many large-scale genetic analyses, including genetically predicted gene expression studies, are predominantly conducted in individuals of European ancestry.[2], [5] This reliance on European populations limits the direct applicability of findings to non-European ancestry groups, as genetic architectures and linkage disequilibrium (LD) patterns can vary substantially across populations. For instance, the use of European LD scores in multi-ancestry or cross-ancestry analyses can introduce methodological limitations.[2], [4] While efforts are made to adjust for population stratification using methods like principal component analysis, such adjustments may not fully capture all nuances of genetic ancestry.[9], [10] Challenges also exist in the precise phenotypic representation and within current research models. There is an acknowledged need for increased representation of female reproductive organs in tissue models to enhance the discovery and validation of relevant genetic associations.[2] The distinction between “race” as a social construct and “genetically informed ancestry” is critical; while studies may use a combination of both due to dataset limitations, genetic ancestry is recognized as the more appropriate descriptor for population stratification in genetic studies.[2] This highlights the ongoing need for improved data collection methods that accurately capture genetic diversity.
Remaining Knowledge Gaps and Future Directions
Section titled “Remaining Knowledge Gaps and Future Directions”Despite significant advancements, research on ovarian reserve and related reproductive traits still faces considerable knowledge gaps. A notable limitation is the absence of comprehensive sex-specific summary-level data, which is crucial for validating findings and providing a more nuanced understanding of sex-influenced genetic effects.[8] Current tissue models, particularly those for gene expression analysis, often have limited samples specifically from female reproductive organs, hindering the power to detect significant associations in these critical tissues.[2]This directly impacts the ability to fully elucidate the molecular mechanisms underlying ovarian reserve.
Addressing these gaps requires ongoing efforts to expand research resources. Future investigations need to prioritize the development of more robust resources for gene expression of female reproductive tissues, such as the uterus, to improve the utility of advanced genetic analyses like transcriptome-wide association studies.[2] Furthermore, enhancing data collection methods in large genomic studies to incorporate precise genetic ancestry or other robust population descriptors is essential for improving the accuracy and generalizability of findings across all populations.[2] These remaining knowledge gaps underscore the dynamic nature of genetic research and the continuous need for refinement in methodologies and data collection.
Variants
Section titled “Variants”Genetic variations, such as single nucleotide polymorphisms (SNPs), can profoundly influence complex biological processes, including ovarian reserve, by affecting gene expression and protein function. The long intergenic non-coding RNAs_LINC01320_ and _LINC01108_, along with the _RNU6-793P_ pseudogene, represent regions where variants like *rs6543833 * and *rs12213875 *may exert regulatory control. LincRNAs are known to modulate gene expression through various mechanisms, such as acting as scaffolds for protein complexes or influencing chromatin structure, while pseudogenes can sometimes act as microRNA sponges, thereby affecting the stability of messenger RNAs. Alterations in these regulatory elements can impact critical pathways in ovarian development and function, potentially leading to variations in the number and quality of ovarian follicles and affecting overall ovarian reserve. Such regulatory influences are crucial for maintaining proper endocrine balance, which is a key aspect of reproductive health . These genetic factors contribute to the broader spectrum of reproductive traits and conditions.[11]Other variants affecting receptor function and signaling pathways also play roles in ovarian reserve. The_GRIN2B_gene encodes a subunit of the N-methyl-D-aspartate (NMDA) receptor, a critical component of glutamate signaling primarily known for its neurological functions, but also present in reproductive tissues. The variant*rs6488619 * within _GRIN2B_could influence the receptor’s activity or expression, thereby modulating neurotransmission and cellular responses. Glutamate signaling has been implicated in ovarian physiology, including the regulation of follicular growth and oocyte maturation, suggesting that altered_GRIN2B_ function could impact the quality and quantity of a woman’s oocytes. Similarly, _NPR3_encodes Natriuretic Peptide Receptor 3, a clearance receptor that regulates the bioavailability of natriuretic peptides, which are involved in cardiovascular health and various endocrine processes . The*rs10061804 * variant in _NPR3_might alter peptide clearance, leading to dysregulated signaling that could affect ovarian angiogenesis, follicular development, and the overall ovarian microenvironment, thereby influencing ovarian reserve. The broader implications of genetic variations on reproductive health are a subject of ongoing research.[11]The integrity of the extracellular matrix and precise developmental signaling are also vital for maintaining ovarian reserve. The inter-alpha-trypsin inhibitor heavy chains,_ITIH5_ and _ITIH2_, are involved in stabilizing the extracellular matrix and protecting against proteolytic degradation. A variant like *rs11255291 * in this region could affect the structural support of developing follicles, potentially compromising oocyte maturation and ovulation, which are critical aspects of ovarian function. Furthermore, the _WNT7A_ gene is a key player in the Wnt signaling pathway, essential for cell proliferation, differentiation, and the proper development of reproductive organs. The *rs9875589 * variant near _WNT7A_ could disrupt this critical signaling, impairing follicular recruitment and survival. Lastly, the _SRSF3P1_ pseudogene and _TMEM86A_ transmembrane protein, with the variant *rs12295403 *, may influence gene expression regulation through splicing or affect membrane-related cellular processes essential for ovarian cell viability and function. These diverse genetic influences collectively underscore the complex genetic architecture underlying ovarian reserve and female reproductive health.[11], [12]
Key Variants
Section titled “Key Variants”Causes
Section titled “Causes”The researchs context does not contain information about the causes of ovarian reserve.
Biological Background of Ovarian Reserve
Section titled “Biological Background of Ovarian Reserve”Ovarian reserve refers to the quantity and quality of oocytes (eggs) remaining in a woman’s ovaries, representing her reproductive potential. It is a critical determinant of fertility and the timing of menopause. The complex interplay of hormones, genetic factors, cellular processes, and systemic health influences the maintenance and depletion of this finite reserve throughout a woman’s life. Understanding these biological underpinnings is essential for assessing reproductive health and addressing related conditions.
Hormonal Regulation of Ovarian Function
Section titled “Hormonal Regulation of Ovarian Function”The maintenance and depletion of ovarian reserve are profoundly influenced by a delicate balance of hormones that orchestrate the female reproductive cycle. Follicle-stimulating hormone (FSH) plays a pivotal role, accelerating oocyte development within the ovaries.[13]Disruptions in FSH production or signaling can have significant consequences for reproductive health, as evidenced by conditions like delayed puberty and hypogonadism caused by mutations in theFSHB gene, which encodes the beta-subunit of FSH.[14]Estrogen, another critical hormone, exerts widespread effects on reproductive tissues through its interaction with estrogen receptors, specificallyERα and ERβ.[15]Estrogen receptor signaling is fundamental during vertebrate development and contributes to the responsiveness of various reproductive organs, including the uterus.[16] The intricate interaction between ERαand other cellular components, such as heat shock proteins like Hsp70, also highlights the complex molecular mechanisms underlying estrogen’s actions.[12]
Genetic Contributions to Reproductive Health
Section titled “Genetic Contributions to Reproductive Health”Genetic mechanisms play a significant role in determining an individual’s ovarian reserve and overall reproductive trajectory. Variations in genes involved in hormone synthesis, receptor function, and cellular development can impact the quantity and quality of oocytes. For instance, mutations in theFSHBgene are directly linked to hypogonadism and delayed puberty, underscoring a clear genetic influence on the initiation and maintenance of ovarian function.[14]Beyond direct hormonal pathways, broader genetic influences on reproductive health are being investigated through large-scale studies. These include genome-wide association studies (GWAS) that identify common genetic origins for conditions like uterine leiomyomata and endometriosis, which, while not directly ovarian reserve, point to shared genetic susceptibilities within the female reproductive system.[7] Such genetic predispositions can influence the overall health and environment of the ovaries, indirectly affecting the reserve.
Cellular and Molecular Dynamics in Ovarian and Reproductive Tissues
Section titled “Cellular and Molecular Dynamics in Ovarian and Reproductive Tissues”Cellular functions and molecular pathways within the ovaries and associated reproductive tissues are crucial for sustaining ovarian reserve. Oocyte development, a complex cellular process, is directly impacted by hormones such as FSH.[13] Beyond direct hormonal action, various intracellular signaling pathways and regulatory networks contribute to cell growth, differentiation, and survival in reproductive organs. For example, in uterine tissues, pathways such as the WNT/β-catenin pathway, the SRF-FOS-JUNB pathway, and the p19Arf-TP53-CDKN1A axis are involved in cellular proliferation and differentiation, with their dysregulation contributing to conditions like uterine leiomyomas.[17], [18], [19]These molecular mechanisms often involve key biomolecules like transcription factors and regulatory proteins. Myocardin, for instance, functions as an inducer of growth arrest and differentiation in smooth muscle cells, and its activity can be inhibited byERα in uterine fibroids, demonstrating complex regulatory networks.[20], [21], [22] While these examples are primarily drawn from uterine biology, the fundamental nature of these cellular and molecular pathways suggests their broader relevance to maintaining cellular homeostasis and function across all reproductive tissues, including the delicate environment of the ovarian follicles.
Systemic and Pathophysiological Influences on Reproductive Capacity
Section titled “Systemic and Pathophysiological Influences on Reproductive Capacity”Ovarian reserve is not an isolated biological trait but is intricately linked to systemic health and can be affected by various pathophysiological processes. Conditions such as uterine leiomyomata (fibroids) and endometriosis represent significant disruptions within the female reproductive system, often associated with altered hormonal environments and inflammatory responses.[23], [24], [25], [26]The presence of estrogen receptors (ERα and ERβ) in uterine fibroids highlights the role of hormone responsiveness in these conditions.[15]Furthermore, broader systemic factors, including metabolic processes like obesity and conditions like hypertension, have been epidemiologically linked to reproductive health issues such as uterine leiomyomata and endometrial cancer.[1], [27]While the direct impact on ovarian reserve may not always be explicit in these contexts, the overall health of the reproductive system and the systemic hormonal and metabolic milieu inevitably influence ovarian function and the rate of oocyte depletion. The existence of large consortia dedicated to studying ovarian cancer underscores the ongoing investigation into pathological processes affecting the ovaries.[28], [29]
Hormonal Signaling and Reproductive Axis Regulation
Section titled “Hormonal Signaling and Reproductive Axis Regulation”The intricate balance of ovarian reserve is fundamentally governed by hormonal signaling, initiating through receptor activation and propagating via intracellular cascades. Follicle-stimulating hormone (FSH) plays a critical role, as evidenced by mutations in its beta-subunit gene, FSHB, which can lead to delayed puberty and hypogonadism, thereby directly impairing the development and function of the reproductive system.[14] Beyond FSH, estrogen receptor signaling is a cornerstone of vertebrate reproductive development.[16]with estrogen and progesterone receptors mediating vital hormonal responses in reproductive tissues.[30] Progestins further contribute to this regulatory network by influencing cellular proliferation.[31] highlighting the complex interplay of these hormones in maintaining reproductive capacity.
Genetic Determinants and Cellular Maintenance Pathways
Section titled “Genetic Determinants and Cellular Maintenance Pathways”Genetic predisposition significantly influences the trajectory of ovarian reserve, particularly concerning the timing of menopause. Meta-analyses have identified 13 distinct genetic loci associated with age at menopause.[32] which serves as a clinical proxy for the depletion of ovarian follicles. These genetic insights underscore the importance of DNA repair and immune pathways in maintaining the long-term viability of ovarian cells.[32] Effective DNA repair mechanisms are essential for preserving the genomic integrity of oocytes and supporting cells, while immune pathways likely modulate the ovarian microenvironment, influencing follicle survival and overall ovarian health through sophisticated gene regulation and cellular maintenance processes.
Oocyte Maturation and Follicular Dynamics
Section titled “Oocyte Maturation and Follicular Dynamics”The dynamic process of oocyte maturation and follicular development is intricately controlled, with FSHacting as a primary driver. Follicle-stimulating hormone accelerates oocyte development in vivo.[13] orchestrating the progression of follicles through various growth stages. The precise activation of FSH receptors and subsequent intracellular signaling cascades are paramount for successful oocyte development and the maintenance of a healthy follicular pool. Disruptions to this crucial pathway, such as those caused by genetic mutations in the FSHB gene, lead to severe consequences like hypogonadism.[14]directly compromising the functional aspects of ovarian reserve and reproductive potential.
Systems-Level Integration and Disease Mechanisms
Section titled “Systems-Level Integration and Disease Mechanisms”Ovarian reserve is influenced by complex, integrated physiological networks, where multiple pathways crosstalk to maintain reproductive homeostasis. Systemic factors, including metabolic aspects related to muscle performance and physical activity in peri-menopausal and post-menopausal women.[33]collectively contribute to ovarian function. Pathway dysregulation represents a key disease-relevant mechanism; for instance,FSHB gene mutations lead to hypogonadism.[14]directly impacting ovarian reserve. WhileFOXO3aderegulation is observed in uterine smooth muscle tumors.[34] this highlights how critical transcription factor regulation can be perturbed in reproductive tissues, potentially affecting cellular proliferation and homeostasis across the reproductive system and offering insights into potential therapeutic targets.
Impact on Reproductive Aging and Systemic Health
Section titled “Impact on Reproductive Aging and Systemic Health”Ovarian reserve is a fundamental determinant of a woman’s reproductive lifespan, directly influencing the onset of menopause. Research investigating metabolic-syndrome pathways and plasma C-reactive protein, such as the Women’s Genome Health Study, highlights the necessity of adjusting for menopausal status when examining associated genetic loci.[35]This suggests an indirect clinical relevance for ovarian reserve, as its decline leads to shifts in hormonal profiles that may impact broader systemic health outcomes, including metabolic and cardiovascular health. The consistent consideration of menopausal status in these large-scale studies underscores its role as an important indicator of reproductive aging, a process fundamentally governed by ovarian reserve.
Frequently Asked Questions About Ovarian Reserve
Section titled “Frequently Asked Questions About Ovarian Reserve”These questions address the most important and specific aspects of ovarian reserve based on current genetic research.
1. My mom had early menopause; will I too?
Section titled “1. My mom had early menopause; will I too?”Yes, there’s a good chance. Your initial ovarian reserve and how quickly it declines are influenced by genetic factors passed down in families. This can affect your reproductive timeline, potentially leading to earlier menopause similar to your mother.
2. Why do some friends get pregnant easily, but I struggle?
Section titled “2. Why do some friends get pregnant easily, but I struggle?”It’s often due to individual differences in ovarian reserve. The rate at which your egg supply declines varies significantly from person to person, and genetic factors play a role in this variability. This means some women naturally have a longer or more robust fertility window than others.
3. Is it true my egg supply is fixed from birth?
Section titled “3. Is it true my egg supply is fixed from birth?”Yes, that’s correct. Your total number of egg cells, or ovarian reserve, is established even before you are born. This finite supply then naturally decreases throughout your life, eventually leading to menopause.
4. What would a fertility test tell me about my eggs?
Section titled “4. What would a fertility test tell me about my eggs?”A fertility test can assess your ovarian reserve by looking at key markers. It typically measures hormones like Anti-Müllerian Hormone (AMH) and Follicle-Stimulating Hormone (FSH), and checks your Antral Follicle Count (AFC) via ultrasound. This helps predict your response to fertility treatments and gives an idea of your current egg supply.
5. I’m older, can I still have kids naturally?
Section titled “5. I’m older, can I still have kids naturally?”Your ability to conceive naturally as you age depends on your individual ovarian reserve. While it naturally declines over time, the rate varies significantly among women. Assessing your ovarian reserve can help you understand your current reproductive potential and inform family planning decisions.
6. Can I do anything to improve my egg quality?
Section titled “6. Can I do anything to improve my egg quality?”The article focuses on the natural decline and assessment of ovarian reserve, which is largely influenced by genetics and established early in life. While lifestyle can impact overall health, the fundamental number and quality of your eggs are primarily determined by factors beyond direct daily control. Fertility preservation options like egg freezing can be considered if you wish to postpone pregnancy.
7. My sister has many eggs, but I don’t. Why?
Section titled “7. My sister has many eggs, but I don’t. Why?”This difference is common and often comes down to individual genetic variations. Even within families, genetic factors influence both the initial number of eggs you start with and the unique rate at which your ovarian reserve declines. This leads to diverse reproductive experiences among siblings.
8. Does my ethnic background affect my egg reserve?
Section titled “8. Does my ethnic background affect my egg reserve?”Research suggests that genetic factors influencing ovarian reserve can vary across different populations. While many studies have focused on individuals of European ancestry, it’s recognized that genetic architectures can differ, meaning your background might influence your specific risk factors.
9. Should I freeze my eggs just in case?
Section titled “9. Should I freeze my eggs just in case?”Freezing your eggs is a fertility preservation option to consider if you wish to delay pregnancy. Understanding your current ovarian reserve can help you make an informed decision about whether it’s a suitable option for your personal timeline and goals.
10. Does daily stress affect my egg count?
Section titled “10. Does daily stress affect my egg count?”While general health and well-being are important, your ovarian reserve, meaning your egg count, is primarily determined by genetic factors and declines naturally over time. The article does not indicate that daily stress directly impacts thenumber of eggs you have.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
Section titled “References”[1] Masuda, T., et al. “GWAS of five gynecologic diseases and cross-trait analysis in Japanese.” European Journal of Human Genetics, vol. 27, no. 11, 2019, pp. 1762-1773.
[2] Kim, J., et al. “Genome-wide meta-analysis identifies novel risk loci for uterine fibroids within and across multiple ancestry groups.” Nat Commun, 2024.
[3] Turnbull, C., et al. “Genome-wide association study identifies five new breast cancer susceptibility loci.”Nat Genet, 2010.
[4] Sliz, E. et al. “Evidence of a causal effect of genetic tendency to gain muscle mass on uterine leiomyomata.”Nat Commun, vol. 14, no. 1, 2023, p. 574.
[5] Austin-Zimmerman, I., et al. “Genome-wide association studies and cross-population meta-analyses investigating short and long sleep duration.” Nat Commun, 2023.
[6] Verbanck, M., Chen, C. Y., Neale, B. & Do, R. “Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases.” Nat Genet, 2018.
[7] Gallagher, C. S. et al. “Genome-wide association and epidemiological analyses reveal common genetic origins between uterine leiomyomata and endometriosis.”Nat Commun, vol. 10, no. 1, 2019, p. 4837.
[8] Wu, X., et al. “A Comprehensive Genome-Wide Cross-Trait Analysis of Sexual Factors and Uterine Leiomyoma.” PLoS Genetics, vol. 19, no. 5, 2023, e1011111. PMID: 38701081.
[9] Carrasquillo, M. M., et al. “Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer’s disease.”Nat Genet, 2009.
[10] Weedon, M. N., et al. “A common variant of HMGA2 is associated with adult and childhood height in the general population.” Nat Genet, 2007.
[11] Wu, X., et al. “A comprehensive genome-wide cross-trait analysis of sexual factors and uterine leiomyoma.” PLoS Genet, 2024.
[12] Dhamad, A. E. et al. “Systematic proteomic identification of the heat shock proteins (Hsp) that interact with estrogen receptor alpha (ERα) and biochemical characterization of the ERα-Hsp70 interaction.”PLoS ONE, vol. 11, no. 1, 2016, pp. 1-19.
[13] Demeestere I, et al. “Follicle-stimulating hormone accelerates mouse oocyte development in vivo.”Biol. Reprod., vol. 87, 2012, pp. 1–11.
[14] Layman L C, et al. “Delayed puberty and hypogonadism caused by mutations in the follicle-stimulating hormone beta-subunit gene.”N. Engl. J. Med., vol. 337, 1997, pp. 607–611.
[15] Bakas, P. et al. “Estrogen receptor α and β in uterine fibroids: a basis for altered estrogen responsiveness.”Fertil. Steril., vol. 90, no. 5, 2008, pp. 1878-1885.
[16] Bondesson M, Hao R, Lin C Y, Williams C, & Gustafsson J A. “Estrogen receptor signaling during vertebrate development.”Biochim Biophys. Acta, vol. 1849, 2015, pp. 142–151.
[17] Ono, M. et al. “Paracrine activation of WNT/β-catenin pathway in uterine leiomyoma stem cells promotes tumor growth.” Proc. Natl Acad. Sci. USA, vol. 110, no. 43, 2013, pp. 17053-17058.
[18] Raimundo, N. et al. “Downregulation of SRF-FOS-JUNB pathway in fumarate hydratase deficiency and in uterine leiomyomas.”Oncogene, vol. 28, no. 10, 2009, pp. 1261-1273.
[19] Markowski, D. N. et al. “HMGA2 and the p19Arf-TP53-CDKN1A axis: a delicate balance in the growth of uterine leiomyomas.” Genes Chromosomes Cancer, vol. 49, no. 7, 2010, pp. 661-668.
[20] Kimura, Y. et al. “Myocardin functions as an effective inducer of growth arrest and differentiation in human uterine leiomyosarcoma cells.” Cancer Res., vol. 70, no. 2, 2010, pp. 501-511.
[21] Chen, J. et al. “Myocardin: a component of a molecular switch for smooth muscle differentiation.”J. Mol. Cell. Cardiol., vol. 34, no. 11, 2002, pp. 1345-1356.
[22] Liao, X. H. et al. “ERα inhibited myocardin-induced differentiation in uterine fibroids.” Exp. Cell Res., vol. 350, no. 1, 2017, pp. 73-82.
[23] Marshall, L. M. et al. “A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata.” Fertil. Steril., vol. 84, no. 5, 2005, pp. 1409-1418.
[24] Missmer, S. A. & Cramer, D. W. “The epidemiology of endometriosis.”Obstet. Gynecol. Clin. North Am., vol. 30, no. 1, 2003, pp. 1-19.
[25] Zondervan, K. T. et al. “Endometriosis.”Nat. Rev. Dis. Prim., vol. 4, no. 1, 2018, p. 9.
[26] Shafrir, A. L. et al. “Risk for and consequences of endometriosis: a critical epidemiologic review.”Best. Pr. Res. Clin. Obstet. Gynaecol., vol. 51, 2018, pp. 1-15.
[27] Boynton-Jarrett, R. et al. “A prospective study of hypertension and risk of uterine leiomyomata.”Am. J. Epidemiol., vol. 161, no. 7, 2005, pp. 628-638.
[28] Ahmed, S. et al. “Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2.”Nat Genet, vol. 39, no. 5, 2007, pp. 651-655.
[29] Song, H. et al. “A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.”Nat Genet, vol. 41, no. 9, 2009, pp. 996-1000.
[30] Ehrlich CE, Young PC, Cleary RE. “Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications.”Am J Obstet Gynecol, vol. 141, 1981, pp. 539–546.
[31] Clarke CL, Sutherland RL. “Progestin regulation of cellular proliferation.” Endocr Rev, vol. 11, 1990, pp. 266–301.
[32] Stolk L, Perry JRB, Chasman DI, He C, Mangino M, Sulem P, et al. “Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways.”Nat Genet, vol. 44, 2012.
[33] Sipilä S, Poutamo J. “Muscle performance, sex hormones and training in peri-menopausal and post-menopausal women.”Scand. J. Med. Sci. Sport, vol. 13, 2003, pp. 19–25.
[34] de Almeida T G, et al. “FOXO3aderegulation in uterine smooth muscle tumors.”Clinics, vol. 79, 2024, p. 100350.
[35] Ridker, Paul M., et al. “Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women’s Genome Health Study.”The American Journal of Human Genetics, vol. 82, no. 5, 2008, pp. 1185-1192.